Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MOREWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORETo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MOREUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don’t find the answers you’re looking for, contact us for additional assistance.
EXPLORE MOREOne potential approach to achieving a functional HIV cure is to first reduce the size of the HIV reservoir and then engineer an immune response that can effectively control the shrunken reservoir in the absence of antiretroviral therapy. MicAbodies, comprised of full-length broadly neutralizing HIV antibodies coupled to a mutated ligand, selectively engage a mutant receptor that has been engineered as a chimeric antigen receptor (CAR) and expressed on CD8 T cells (convertibleCAR-T cells). The HIV-specific MicAbodies and the convertibleCAR-T cells can detect and eliminate HIV infected cells. The modularity of the convertibleCAR-T cell system allows multiplexing with several anti-HIV antibodies and yields greater breadth and control, thus making this platform a promising tool for attacking the latent HIV reservoir.
Creative Biolabs invited Dr. Eytan Herzig, a Staff Research Scientist in the Gladstone Center for HIV Cure Research, to share his profound insights on the principles and opportunities of innovative convertibleCAR-T platform in HIV cure.
During this webinar, the following topics were discussed:
Webinar Recording
Speaker Bio
Dr. Eytan Herzig is a Staff Research Scientist in the Gladstone Center for HIV Cure Research, where he leads the use of new technologies to fight HIV. After completing his Ph.D. education at the Tel Aviv University, he worked as a postdoctoral fellow at Tel Aviv University and at Gladstone.
All services and products are only for lab research use, not for any clinical diagnosis or treatment.
For any technical issues or products/services related questions, please leave your information below. Our team will contact you soon.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.
LEARN MORE
Angiotensin-converting Enzyme 2 (ACE2)-CHO Cell Line Model for COVID-19: Helps researchers to further study the interaction between the receptor ACE2 and the COVID-19 virus.
LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.
LEARN MORE
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE
